

Sutter Institute for Medical Research (SIMR)
2800 L Street, Suite 410
Sacramento, Ca 95816

SIMR Patient Recruitment Services
Toll Free Contact us at: 877-494-3444
Oncology 916-454-6595

Breast Cancer Studies

DCIS (NSABP B-43) - A phase III randomized trial comparing Trastuzumab given concurrently with Radiation Therapy and Radiation Therapy alone for women with HER2-Positive Ductal Carcinoma In Situ resected by lumpectomy. HER2 status determined by central testing prior to randomization.

NOVARTIS Z-ACT-1 A phase IV, open-label, randomized trial to evaluate the anti-cancer effects of zoledronic acid and circulating tumor cell measurements in patients with HER2-negative metastatic breast cancer without bone metastasis.

NSABP B-46I - A phase III, open-label, randomized trial comparing Docetaxel & Cyclophosphamide plus/minus Bevacizumab and Doxorubicin, Cyclophosphamide & Docetaxel alone for women with node-positive or high-risk node-negative, HER2-negative invasive adenocarcinoma of the breast.

NSABP B-47 - A phase III randomized trial comparing Chemotherapy alone to Chemotherapy plus Trastuzumab in women with node-positive or high-risk node-negative HER2-low invasive breast cancer.

SWOG S0221 - A phase III randomized trial of dose dense post-operative adjuvant therapy in node-positive or high-risk node-negative breast cancer patients.

Lung Studies

ECOG E1505 - A phase III randomized trial of adjuvant chemotherapy with or without Bevacizumab for patients with completely resected Stage IB-IIIa Non-Small Cell Lung Cancer (NSCLC)

ECOG E5508 - A phase III maintenance therapy with Bevacizumab, Pemetrexed or a combination of Bevacizumab and Pemetrexed following Carboplatin, Paclitaxel and Bevacizumab for advanced Non-Squamous NSCLC

GSK MAGRIT - A phase III double-blind, randomized, placebo-controlled study to assess the efficacy of MAGE-A3 ASCI as adjuvant therapy in patients with resectable MAGE-A3 positive NSCLC.

IMCL CP12-0917 - A phase II, first-line treatment of patients with recurrent or advanced NSCLC.

IMCL CP11-0806 - A phase III, first-line treatment of patients with advanced squamous NSCLC with Necitumumab and Gemcitabine-Cisplatin.

SWOG S0720 - A phase II gene expression based adjuvant therapy study in patients with resected early stage NSCLC.

SWOG S0819 - A phase III randomized study of patients with newly diagnosed metastatic NSCLC comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without Cetuximab.

GI Studies

CALGB/SWOG C80702 - A phase III study of 6 vs. 12 treatments of adjuvant FOLFOX plus Celecoxib or placebo for patients with resected Stage III colon cancer.

SWOG S0713 - A Phase II study of Oxaliplatin, Capecitabine, Cetuximab and Radiation in pre-operative therapy of rectal cancer.

PPHM1002 - A phase II randomized study of Gemcitabine with or without Bavutuximab in patients with previously untreated advanced pancreatic cancer.

GYN Studies

GOG 0252 - A phase III study of Bevacizumab with IV vs. IP chemotherapy in ovarian, Fallopian Tube and Primary Peritoneal stage II and only stage III cancer with no residual disease greater than 1 cm.

GOG 0262 - A phase III study of Paclitaxel vs. dose dense weekly Paclitaxel in combination with Carboplatin with or without concurrent and consolidation Bevacizumab in the treatment of primary stage III or IV epithelial ovarian, peritoneal or fallopian tube cancer.

Prevention Studies

NCCTG N08ca - A phase III randomized, double-blind, placebo-controlled study using Glutathione (GSH) for prevention of Paclitaxel/Carboplatin induced peripheral neuropathy

GU Studies

S0931 EVEREST - A phase III study of Everolimus for renal cancer ensuing surgical therapy.

EFC118784: FIRSTANA - A phase III randomized, open label study comparing Cabazitaxel at 25mg/m² and 20mg/m² in combination with Prednisone to Docetaxel in combination with Prednisone in patients with metastatic Castration Resistant Prostate Cancer that have not previously been treated with chemotherapy.



*Sutter Institute for
Medical Research*